Merck: Keytruda gets positive EU opinion
(CercleFinance.com) - Keytruda, Merck's immunotherapy, has received a positive opinion from European health authorities for the treatment of lung cancer.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending Merck's anti-PD-1 therapy, in combination with chemotherapy, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults.
The move was based on a trial that showed a significant improvement in overall survival and progression-free survival compared with chemotherapy alone.
The decision by the European Commission is expected in the first quarter of 2019.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending Merck's anti-PD-1 therapy, in combination with chemotherapy, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults.
The move was based on a trial that showed a significant improvement in overall survival and progression-free survival compared with chemotherapy alone.
The decision by the European Commission is expected in the first quarter of 2019.
Copyright (c) 2019 CercleFinance.com. All rights reserved.